secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001104659-23-073005
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Life Sciences re-elects directors, approves equity plan increase, but fails to pass officer exculpation amendment
--------------------------------------------------------------------------------

- Robert Van Nostrand and Jane Wasman re-elected as Class I directors with ~5.45M and ~5.48M votes for, respectively.
- Ratification of Moss Adams LLP as independent auditor for FY2023 approved: 13.5M for, 1.0M against, 0.8M abstain.
- Amendment to 2019 Equity Incentive Plan increasing authorized shares by 3 million approved: 4.68M for, 3.27M against.
- Proposal to amend certificate of incorporation for officer exculpation failed; required majority of outstanding shares — only 6.04M of 15.30M voted for.
- Non-binding advisory vote on executive compensation passed: 4.77M for, 3.08M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465923073005/0001104659-23-073005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465923073005/tm2319255d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-073005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer